Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Stakeholder Opinions Head and Neck Cancer

Stakeholder Opinions Head and Neck Cancer

Key issues in head and neck cancer including disease overview and epidemiology, current treatment patterns and controversies, unmet needs and key stakeholder opinions. The clinical pipeline and profiles of the late-phase products are also included.

Incidence of head and neck cancer across the seven major markets in 2007 is estimated to total 137,299. Forty percent of these cases present with stage III/IV disease, when patient prognosis is poor. Cisplatin-based therapy continues to dominate treatment, although the toxicities associated with this approach highlights the need for more tolerable alternatives, such as Erbitux.

Scope

Head and neck cancer epidemiology, disease diagnosis and multi-modality treatment approaches Remaining unmet needs in the treatment of head and neck cancer Research and analysis of the head and neck cancer pipeline with in-depth clinical and commercial assessment of Phase III candidates Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Highlights

The current treatment of concomitant cisplatin-based chemotherapy and radiotherapy cannot be used in all patients due to their associated toxicities. In light of this, opportunity exists for alternative more tolerable therapies to enter the head and neck cancer market. The majority of head and neck cancer patients present with late stage disease when the survival rate is low. There is therefore a great need for more effective drugs in the metastatic disease setting, in which 5 year survival can be as low as 4%. Molecular targeted therapies dominate the pipeline. Fully human monoclonal antibodies that also target EGFR are showing encouraging clinical potential while also promising to reduce the infusion-related reactions sometimes seen with Erbitux.

Reasons to Purchase

Gain an insight into the epidemiology trends and major risk factors for head and neck cancer Identify the limitations of current head and neck cancer treatment options and consider the remaining unmet needs Acquire a detailed appreciation and impartial perspective of the head and neck cancer pipeline and identify the key products in late-phase development.

Publication Date: 29-Oct-2007 Format PDF
Table of Contents
Price: $3,800.00 / €2,542.20

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions